Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aradigm Corp (ARDM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,608
  • Shares Outstanding, K 15,200
  • Annual Sales, $ 14,470 K
  • Annual Income, $ -10,710 K
  • 36-Month Beta 0.46
  • Price/Sales 1.40
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.27 +2.36%
on 08/15/18
1.53 -15.03%
on 07/19/18
-0.21 (-13.91%)
since 07/17/18
3-Month
1.27 +2.36%
on 08/15/18
2.33 -44.21%
on 06/20/18
-0.12 (-8.45%)
since 05/17/18
52-Week
1.03 +26.21%
on 03/02/18
7.35 -82.31%
on 12/29/17
+0.02 (+1.56%)
since 08/17/17

Most Recent Stories

More News
Aradigm Announces Second Quarter 2018 Financial Results

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2018.

ARDM : 1.30 (+0.78%)
Factors of Influence in 2018, Key Indicators and Opportunity within Community Health, Monotype Imaging, Cardlytics, Sanchez Energy, First Horizon National, and Aradigm -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Community Health Systems, Inc....

CDLX : 20.62 (-2.18%)
CYH : 3.41 (+1.79%)
ARDM : 1.30 (+0.78%)
SN : 2.45 (+1.24%)
TYPE : 21.15 (+0.24%)
FHN : 18.65 (+1.14%)
New Research Coverage Highlights ProPetro Holding, Aradigm, Ocean Power Technologies, Icahn Enterprises, Granite Point Mortgage Trust, and PBF Logistics LP -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ProPetro Holding Corp. (NYSE:PUMP),...

GPMT : 18.70 (-0.05%)
PBFX : 21.55 (+0.47%)
ARDM : 1.30 (+0.78%)
OPTT : 0.76 (+7.04%)
IEP : 79.34 (-0.18%)
PUMP : 16.64 (+4.39%)
Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the appointment of Dr. Theresa Matkovits to the Board, the Audit Committee of the Board and the Nominating and Corporate...

ARDM : 1.30 (+0.78%)
CTRV : 0.66 (unch)
Aradigm Announces First Quarter 2018 Financial Results

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2018.

ARDM : 1.30 (+0.78%)
New Research Coverage Highlights Aradigm, Ultra Petroleum, TRI Pointe Group, Finisar, Tesla, and The Progressive -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aradigm Corporation (NASDAQ:ARDM),...

UPL : 1.05 (-5.41%)
TSLA : 305.50 (-8.93%)
ARDM : 1.30 (+0.78%)
FNSR : 19.13 (+1.22%)
PGR : 66.28 (+1.89%)
TPH : 14.08 (+0.72%)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 1.30 (+0.78%)
BPTH : 1.44 (+1.41%)
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission

Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA)...

ARDM : 1.30 (+0.78%)
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results

--Cash and cash equivalents of $7.1 million expected to be sufficient to fund operations for Q1 2018; temporary measures implemented to preserve cash resources

ARDM : 1.30 (+0.78%)
Aradigm Files MAA for Bronchiectasis Candidate in the EU

Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.

LGND : 247.98 (+3.47%)
ARDM : 1.30 (+0.78%)
ENTA : 92.58 (+3.57%)
REGN : 374.26 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ARDM with:

Business Summary

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via...

See More

Key Turning Points

2nd Resistance Point 1.41
1st Resistance Point 1.36
Last Price 1.30
1st Support Level 1.27
2nd Support Level 1.23

See More

52-Week High 7.35
Fibonacci 61.8% 4.94
Fibonacci 50% 4.19
Fibonacci 38.2% 3.44
Last Price 1.30
52-Week Low 1.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar